Rate control was more cost-effective than rhythm control in persistent atrial fibrillation
- Counting the Cost of Atrial Fibrillation: Use of Wireless Pacemaker Technology to Innovate Care Delivery. McDaniel, Don; D'Orazio, Dan; Sutton, Brad // Modern Healthcare;4/30/2012, Vol. 42 Issue 18, special section p1
No abstract available.
- COMMENTARY: Rate control was more cost-effective than rhythm control in persistent atrial fibrillation. Newman, David // ACP Journal Club;Mar/Apr2005, Vol. 142 Issue 2, p53
The article comments on a study which examines the cost-effectiveness of rate control over rhythm control for reducing cardiovascular morbidity and mortality in patients with persistent atrial fibrillation. The study did not identify a strategy-dependent difference in efficacy outcomes between...
- Perioperative Sublingual Isosorbide Dinitrate for the Prevention of Cardiac Complications in Cardiac Patients Undergoing Noncardiac Surgery. RuDusky, Basil M. // Angiology;Nov/Dec2005, Vol. 56 Issue 6, p755
One hundred fifty-two consecutive patients with a known or suspected diagnosis of atherosclerotic coronary artery disease were administered 5 mg sublingual isosorbide dinitrate 2 hours and Â½ hour preoperatively and every 4 hours postoperatively for 3 days, for the prevention of cardiovascular...
- Atrial Fibrillation and Cardiovascular Comorbidities, Survival and Mortality: A Real-Life Observational Study. Clua-Espuny, Jose Luis; Panisello-Tafalla, Anna; Lopez-Pablo, Carlos; Lechuga-Duran, Inigo; Bosch-Princep, Ramon; Lucas-Noll, Jorgina; Gonzalez-Henares, Antonia; Queralt-Tomas, Lluisa; Ripolles-Vicente, Rosa; Calduch-Noll, Cristina; Gonzalez-Rojas, Nuria; Gallofre-Lopez, Miguel // Cardiology Research;2014, Vol. 5 Issue 1, p12
Background:Atrial fibrillation (AF) is the most common cardiac tachyarrhythmia encountered in clinical practice affecting up to 10% of the population over 60 years old and its prevalence rises with age. The main goals were to characterize the AF patient population after the initial diagnosis of...
- The Cost Effectiveness of Anticoagulation Management Services for Patients with Atrial Fibrillation and at High Risk of Stroke in the US. Sullivan, Patrick W.; Arant, Thomas W.; Ellis, Samuel L.; Ulrich, Heather // PharmacoEconomics;2006, Vol. 24 Issue 10, p1021
BACKGROUND: Anticoagulation therapy with warfarin is widely considered the standard of care for stoke prophylaxis in patients with atrial fibrillation who are at high risk of stroke. Community-based studies in the US have reported that the effectiveness of anticoagulation varies by management...
- Rate control is better than rhythm control in atrial fibrillation. // BMJ: British Medical Journal (International Edition);3/8/2003, Vol. 326 Issue 7388, p508
Presents a question and synopsis regarding the preferred strategy in high risk patients with atrial fibrillation: rate control or rhythm control strategy. Goal to keep patients in normal sinus rhythm; Need for multiple episodes of cardioversion and potentially toxic antiarrhythmic drugs;...
- Hospitalisations main cost driver of AF in France. // PharmacoEconomics & Outcomes News;1/31/2004, Issue 445, p12
Discusses research being done on the cost of care associated with treating patients with atrial fibrillation (AF) in France. Reference to a study by J.-Y. Le Heuzey et al, published in the January 2004 issue of the "American Heart Journal"; Costs related to hospitalisations; Difference in the...
- Switching warfarin formulations cost saving? // PharmacoEconomics & Outcomes News;12/8/2012, Issue 668, p8
The article discusses research being done the effect of switching warfarin formulations on healthcare resource use and costs in atrial fibrillation (AF) patients in the U.S.
- Apixaban cost effective in patients with AF in Australia. // PharmacoEconomics & Outcomes News;10/22/2016, Vol. 764 Issue 1, p7
The article discusses findings of a study which evaluates the cost effectiveness of apixaban compared to aspirin as preventive medicine of patients with atrial fibrillation (AF) in Australia.